JPH04342528A - Agent for promotion of alcohol metabolism and acetaldehyde metabolism - Google Patents
Agent for promotion of alcohol metabolism and acetaldehyde metabolismInfo
- Publication number
- JPH04342528A JPH04342528A JP14124691A JP14124691A JPH04342528A JP H04342528 A JPH04342528 A JP H04342528A JP 14124691 A JP14124691 A JP 14124691A JP 14124691 A JP14124691 A JP 14124691A JP H04342528 A JPH04342528 A JP H04342528A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- kinds
- metabolism
- acetaldehyde
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims description 45
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 title claims description 42
- 230000004060 metabolic process Effects 0.000 title claims description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 38
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 28
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960002477 riboflavin Drugs 0.000 claims abstract description 25
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 22
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 22
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 22
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 13
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 13
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 13
- 239000011718 vitamin C Substances 0.000 claims abstract description 13
- 235000018417 cysteine Nutrition 0.000 claims abstract description 12
- 229960003495 thiamine Drugs 0.000 claims abstract description 12
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 10
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 10
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 20
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims 3
- 235000019156 vitamin B Nutrition 0.000 claims 3
- 239000011720 vitamin B Substances 0.000 claims 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract description 45
- 229940011671 vitamin b6 Drugs 0.000 abstract description 23
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract description 20
- 235000019158 vitamin B6 Nutrition 0.000 abstract description 20
- 239000011726 vitamin B6 Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000035622 drinking Effects 0.000 abstract description 5
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 abstract description 4
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 abstract description 4
- 150000001945 cysteines Chemical class 0.000 abstract description 3
- 235000008160 pyridoxine Nutrition 0.000 abstract description 3
- 239000011677 pyridoxine Substances 0.000 abstract description 3
- 235000019192 riboflavin Nutrition 0.000 abstract description 3
- 239000002151 riboflavin Substances 0.000 abstract description 3
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 abstract description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 abstract description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 abstract description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 abstract description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 abstract description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 abstract description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 abstract description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 abstract description 2
- 235000008151 pyridoxamine Nutrition 0.000 abstract description 2
- 239000011699 pyridoxamine Substances 0.000 abstract description 2
- 229950001574 riboflavin phosphate Drugs 0.000 abstract description 2
- 235000013334 alcoholic beverage Nutrition 0.000 abstract 1
- 230000001976 improved effect Effects 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 32
- 239000000203 mixture Substances 0.000 description 21
- 238000009472 formulation Methods 0.000 description 13
- 206010019133 Hangover Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 229960002433 cysteine Drugs 0.000 description 10
- 206010033799 Paralysis Diseases 0.000 description 8
- 239000003610 charcoal Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 235000000069 L-ascorbic acid Nutrition 0.000 description 5
- 239000002211 L-ascorbic acid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000013878 L-cysteine Nutrition 0.000 description 3
- 239000004201 L-cysteine Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000004149 ethanol metabolism Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000003016 quadriplegic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 3
- 239000011747 thiamine hydrochloride Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 208000007287 cheilitis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ZLHIRBARVOGMSN-DKWTVANSSA-M sodium;(2r)-2-amino-3-sulfanylpropanoate Chemical compound [Na+].SC[C@H](N)C([O-])=O ZLHIRBARVOGMSN-DKWTVANSSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001385 thiamine disulfide Drugs 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
【0001】
【産業上の利用分野】本発明は、ビタミンB2類および
ビタミンB6類を有効成分として含有することを特徴と
するアルコール代謝およびアセトアルデヒド代謝促進剤
に関するものである。
【0002】
【従来の技術】ビタミンB2類および/またはビタミン
B6類はビタミン剤として広く使われており、その効能
、効果として主に口角炎、口唇炎、口内炎、舌炎、湿疹
、皮膚炎、かぶれ、ただれ、にきび、肌あれ、赤鼻、目
の充血、目のかゆみ並びに妊娠、授乳期および病中病後
の体力低下時の補給などがうたわれている。また、これ
らのビタミンは長期アルコール摂取による欠乏に対し補
給的に投与されることもある。しかし、ビタミンB2類
とビタミンB6類を併用した場合、アルコール代謝およ
びアセトアルデヒド代謝の両者を顕著に促進し、飲酒時
の強度の酩酊の予防、酔い覚ましの促進および二日酔い
の予防治療剤として優れた効果を発揮することは知られ
ていない。また、L−アスコルビン酸およびL−システ
インはアセトアルデヒドの麻酔作用および致死作用に対
する防禦効果を持ち、特にL−アスコルビン酸とL−シ
ステインおよび塩酸チアミンの組み合わせよりなる処方
に優れた効果が有ることはへルベルト・スプリンスらに
よって報告されている[エイジェンツ・アンド・アクシ
ョンズ(Agents and Actions)第5
/2巻、169〜173頁(1975年)]。さらにま
た、ビタミンC、ビタミンB1およびビタミンB6の組
合せが、血中のアルコール濃度を低下させることも知ら
れている(欧州特許公開公報 288610 )。しか
し、アルコール代謝とアルデヒド代謝の両者を促進し、
有効性と安全性が大きく、実用性の高い医薬品はほとん
どないのが現状である。
【0003】
【発明が解決しようとする課題】「酒は百薬の長」と言
われる反面、酒による弊害も多く人体に様々な影響をも
たらし、一部社会問題ともなっている。飲酒によって、
酩酊、悪酔いおよび二日酔いと云った症状が現れ、これ
らの症状はエタノールの中枢抑制作用およびエタノール
が代謝されて生じるアセトアルデヒドによるものとされ
ている。しかしながら、このようなエタノールおよびア
セトアルデヒドによる諸症状の改善および予防に特効薬
がないのが現状である。したがって、アルコール代謝お
よびアセトアルデヒド代謝を促進し、かつ安全性が高く
、実用性の高い医薬品の開発が望まれている。
【0004】
【課題を解決するための手段】本発明者らは、アルコー
ル代謝およびアセトアルデヒド代謝を促進し、飲酒に伴
う酩酊、悪酔いおよび二日酔いなどの諸症状の予防およ
び改善作用を示す化合物について鋭意研究を行った結果
、ビタミンB2類とビタミンB6類を組み合わせた処方
に強い作用を認め、きわめて有用であり、かつ実用性が
高いことを見出し、本発明を完成した。
【0005】つぎに、本発明を詳細に説明する。本発明
はビタミンB2類とビタミンB6類を組み合わせた処方
により、アルコール代謝およびアセトアルデヒド代謝促
進作用を発揮するが、さらに、ビタミンB2類とビタミ
ンB6類に加えてビタミンC類およびシステイン類を含
有する処方とすることにより、または、ビタミンB2類
とビタミンB6類に加えてビタミンC類、システイン類
およびビタミンB1類を含有する処方とすることにより
一段と増強された作用が発揮される。本発明で使用する
ビタミンB2類としては、生体内でビタミンB2作用を
発揮する物質であればよく、たとえば、リボフラビン、
フラビンアデニンジヌクレオチドおよびリン酸リボフラ
ビンなど、更にそれらの生理学的に許容されうる各種エ
ステル(酪酸リボフラビンなど)および各種塩類を挙げ
ることができる。また、本発明で使用するビタミンB6
類としては、生体内でビタミンB6作用を発揮する物質
であればよく、たとえば、ピリドキシン、ピリドキサミ
ンおよびリン酸ピリドキサールなど、更にそれらの生理
学的に許容される各種エステルおよび各種塩類を挙げる
ことができる。ビタミンC類としては、たとえば、L−
アスコルビン酸またはL−アスコルビン酸のナトリウム
塩およびL−アスコルビン酸のカルシウム塩などの生理
学的に許容されうる各種塩類を挙げることができる。シ
ステイン類としては、たとえば、L−システインまたは
L−システインの塩酸塩およびL−システインのナトリ
ウム塩などの生理学的に許容されうる塩類を使用するこ
とができるとともに、グルタチオンを使用することも可
能である。また、ビタミンB1類としては、生体内でビ
タミンB1作用を発揮する物質であればよく、たとえば
、チアミン、塩酸チアミンおよびジスルフィド型チアミ
ンなど、更にそれらの生理学的に許容されうる各種エス
テルおよび各種塩類を挙げることができる。上記本発明
組成物においては、さらに、ビタミンE類、パントテン
酸またはその塩類、パンテチン、ニコチン酸アミドおよ
びビタミンB12類などのような各種ビタミン;利胆剤
;糖類;並びに和漢方剤など適宜配合することができる
。
【0006】本発明組成物は、医薬品または食品の形態
で提供することができ、医薬としては経口、非経口とも
に適用されうる。本発明組成物が提供されうる形態とし
ては、通常知られた剤形、たとえば、経口投与用には、
錠剤、散剤、顆粒、糖衣錠、カプセルおよび液剤など、
非経口投与には、懸濁液、液剤、乳剤、アンプルおよび
注射剤などが挙げられ、これらを組み合わせた形態でも
提供できる。製剤化の際には、製剤の分野で通常知られ
た添加物を適宜使用して製剤化することができる。
【0007】また、本発明組成物の投与方法、投与量お
よび投与回数は、患者の症状によって適宜選択されるが
、各成分の投与量は一般に下記の範囲内で選択すること
ができる。
oビタミンB2類
約 5mg〜100mg/日
oビタミンB6類
約 10mg〜300mg/日
oシステイン類
約 50mg〜500mg/日
oビタミンC類
約 200mg〜5000mg/日
oビタミンB1類
約 5mg〜200mg/日
上記1日投与量を飲酒前、飲酒後あるいは飲酒前後に1
〜数回に分けて投与すればよい。
【0008】つぎに、本発明組成物の効果をエタノール
またはアセトアルデヒド投与時の薬理効果の発現によっ
て説明する。なお、試験は試験法その1およびその2に
よって行った。
(1) 飲酒により手足がマヒしたり、千鳥足になるこ
とは良く知られた現象であり、動物でも一定量以上のエ
タノールまたはアルデヒドを投与した場合、手足がマヒ
し、歩行が異常となり正常状態ではつかまることが可能
な金属棒などにつかまることができなくなる。エタノー
ル代謝およびアセトアルデヒド代謝を促進し、手足のマ
ヒ時間を短縮することは、飲酒時の酔い覚め促進作用を
示すものであり、二日酔いおよび悪酔いの予防および治
療上にも重要である。エタノール代謝およびアセトアル
デヒド代謝促進作用を以下の試験法その1によって検討
した。
(2) 一般に飲酒による二日酔いの症状の一つに胃腸
の不快感や食欲不振などの消化管機能の異常が云われて
いる。動物で消化管機能を測定する一般的な方法の一つ
として腸管炭末輸送能の測定が行われており、エタノー
ルによってマウスの腸管炭末輸送能が障害され低下する
ので、それに対する薬剤の効果を試験法その2において
検討した。以下に、具体的にそれらの試験法を記載する
。
なお、試験に使用した各成分の投与量は表1に示す通り
である。これ以外の投与量の場合は、その投与量を括弧
内に記載する(表7、表8)。また、表2〜9中の処方
の成分は表1に示す略号で記載する。
【0009】
【表1】
使用した各
成分およびその投与量───────────────
─────────────────────
成 分
略 号
投与量
(mg/kg)
───────────────────────
───────────── リボフラビン
VB2
100 酪酸
リボフラビン
VB2but 1
00 ピリドキシン・HCl
VB6
200 L−アスコルビン酸
VC
500 L−システイン・HCl・
H2O Cys
300 塩酸チアミン
VB1
200───────
─────────────────────────
────
【0010】(1) 試験法その1(エタノール代謝お
よびアセトアルデヒド代謝促進効果)
ddy系雄性マウス(約5〜6週齢)を約18〜20時
間絶食し、被験薬剤を経口投与する。被験薬剤投与90
分後、エタノール3.1ml/kgまたはアセトアルデ
ヒド200mg/kgを腹腔内投与する。マウスはエタ
ノールまたはアセトアルデヒド投与により手足がマヒし
、直径1.5mmの金属棒につかまることができなくな
るが、時間とともに回復し、つかまることが可能となる
。前足2本を含む3本以上の足でつかまることができる
ようになるまでの時間をマヒ時間として測定した。なお
、エタノ−ルおよびアセトアルデヒドは適量の食塩液に
混合させ、投与した。また、対照群には食塩液のみをマ
ウス体重10gあたり0.1ml投与した。その結果を
表2〜表8に示す。
【0011】
【表2】
【0012】
【表3】
アセトアルデヒドによるマウス四肢
マヒ作用に及ぼす薬剤投与の影響──────────
─────────────────────────
─ 処 方
使用マウス匹数 平均マヒ
時間(秒)────────────────────
──────────────── 対照群
16 372±15.6
VB2but+VB6
15
284±18.5**───────────────
─────────────────────
t−te
st **P<0
.01
【0013】
【表4】
【0014】
【表5】
【0015】
【表6】
アセトアルデヒドによるマウス四肢マ
ヒ作用に及ぼす薬剤投与の影響───────────
─────────────────────────
処 方
使用マウス匹数 平均マヒ時
間(秒)─────────────────────
─────────────── 対照群
12 434±37
Cys+VC+VB1
12
371±24 Cys+V
C+VB1+VB2but+VB6 12
313±12**
────────────────────────
────────────
t−test
**P<0.01
【0016】
【表7】
エタノールによるマウス四肢マヒ
作用に及ぼす薬剤投与の影響────────────
────────────────────────
処 方(投与量)
使用マウス匹数 平均マヒ時間(分)
(mg/kg)
─────
─────────────────────────
────── 対照群
12
141±6.3 C
ys+VC+VB1
12 126±8.
7 Cys+VC+VB1+VB2
but+VB6 12
96±11.3** Cys+VC
+VB1+VB2but+VB6 12
94± 9.9**
(160) (25) (20)
(100)
───
─────────────────────────
────────
t−test **P<
0.01 【0017】
【表8】
【0018】(2) 試験法その2
ddy系雄性マウス(約5〜6週齢)を約16〜18時
間絶食した後、薬剤を経口投与し、1時間後、エタノー
ル4ml/kgを腹腔内投与する。エタノール投与1.
5時間後、アラビアゴム液0.25mlに懸濁した炭末
を経口投与する。炭末投与40分後、マウスの腸管を取
り出し、胃の幽門部から炭末の先端までの長さ(A)、
および胃の幽門部から盲腸までの長さ(B)を測定し、
次式にしたがって腸管炭末輸送率を求める。
炭末輸送率はエタノールを投与しない場合(正常
の場合)平均50〜60%程度の値を示し、エタノール
4ml/kgを腹腔内に投与した場合20〜30%程度
の値に低下する。
この時薬剤を投与した場合の結果を表9に示す。
【0019】
【表9】
【0020】以上の結果を総合的に判断すると、本発明
はビタミンB2類とビタミンB6類を併用することによ
り、アルコール代謝およびアセトアルデヒド代謝促進作
用を発揮することがわかり、さらには、ビタミンB2類
とビタミンB6類にビタミンC類およびシステイン類を
含有する処方とすること、または、ビタミンB2類 と
ビタミンB6類にビタミンC類、システイン類およびビ
タミンB1類を含有する処方とすることにより一段と増
強された作用が発揮されることがわかる。また、ビタミ
ンB2類とビタミンB6類を加えた処方は優れた効果を
示し、飲酒による二日酔い時の胃腸症状の発現予防およ
び治療にも有用であることがわかる。
【0021】
【実施例】つぎに、製剤を実施例として示すが、製剤は
これらにのみ限定されるものではない。
実施例1
1カプセル当り下記組成のカプセル剤は、公知の手段に
よって製造することができる。
【0022】実施例2
1包当り下記組成の細粒剤は公知の手段によって製造す
ることができる。
【0023】実施例3
1包当り下記組成の細粒剤は公知の手段によって製造す
ることができる。
【0024】
【発明の効果】本発明のビタミンB2類とビタミンB6
類を組み合わせた処方により、アルコール代謝およびア
セトアルデヒド代謝促進作用を発揮できるが、さらに、
ビタミンB2類およびビタミンB6類にビタミンC類お
よびシステイン類を含有する処方とすること、または、
ビタミンB2類およびビタミンB6類にビタミンC類、
システイン類およびビタミンB1類を含有する処方とす
ることにより一段と増強された作用が発揮される。よっ
て、本発明は二日酔いおよび悪酔いの予防および治療に
有用なものである。Detailed Description of the Invention [0001] [Industrial Application Field] The present invention relates to an alcohol metabolism and acetaldehyde metabolism promoter characterized by containing vitamin B2s and vitamin B6s as active ingredients. . [Prior Art] Vitamin B2 and/or vitamin B6 are widely used as vitamin preparations, and their efficacy and effects are mainly for angular cheilitis, cheilitis, stomatitis, glossitis, eczema, dermatitis, It is said to be a good supplement for rashes, sores, acne, rough skin, red noses, red eyes, itchy eyes, as well as during pregnancy, breastfeeding, and when physical strength declines during or after illness. These vitamins may also be given as supplements to treat deficiencies caused by long-term alcohol consumption. However, when vitamin B2 and vitamin B6 are used together, they significantly promote both alcohol metabolism and acetaldehyde metabolism, and are effective as prevention agents for preventing severe drunkenness, promoting sobering up, and preventing and treating hangovers. is not known to exhibit. In addition, L-ascorbic acid and L-cysteine have a protective effect against the anesthetic and lethal effects of acetaldehyde, and it is said that a formulation consisting of a combination of L-ascorbic acid, L-cysteine, and thiamine hydrochloride is particularly effective. Reported by Ruberto Splins et al. [Agents and Actions, No. 5]
/ vol. 2, pp. 169-173 (1975)]. Furthermore, a combination of vitamin C, vitamin B1 and vitamin B6 is also known to reduce blood alcohol levels (European Patent Publication No. 288610). However, it promotes both alcohol metabolism and aldehyde metabolism,
At present, there are almost no pharmaceuticals that are highly effective, safe, and highly practical. [0003]Problems to be Solved by the InventionAlthough alcohol is said to be the best medicine, alcohol has many harmful effects on the human body, and has even become a social problem. By drinking,
Symptoms such as drunkenness, hangover, and hangover appear, and these symptoms are said to be caused by the central depressant effect of ethanol and acetaldehyde produced when ethanol is metabolized. However, there is currently no specific drug for improving or preventing the various symptoms caused by ethanol and acetaldehyde. Therefore, it is desired to develop a drug that promotes alcohol metabolism and acetaldehyde metabolism, is highly safe, and is highly practical. [Means for Solving the Problems] The present inventors have conducted extensive research on compounds that promote alcohol metabolism and acetaldehyde metabolism and have the effect of preventing and improving various symptoms associated with drinking, such as drunkenness, hangovers, and hangovers. As a result, they found that a combination of vitamin B2 and vitamin B6 has a strong effect, is extremely useful, and has high practicality, and has completed the present invention. Next, the present invention will be explained in detail. The present invention has a formulation that combines vitamin B2 and vitamin B6 to promote alcohol metabolism and acetaldehyde metabolism, but also contains vitamin C and cysteine in addition to vitamin B2 and vitamin B6. A further enhanced effect can be exerted by using a formulation containing vitamin C, cysteine, and vitamin B1 in addition to vitamin B2 and vitamin B6. The vitamin B2 species used in the present invention may be any substance that exhibits vitamin B2 action in vivo, such as riboflavin,
Mention may be made of flavin adenine dinucleotide and riboflavin phosphate, as well as various physiologically acceptable esters thereof (such as riboflavin butyrate) and various salts thereof. In addition, vitamin B6 used in the present invention
Substances that exhibit vitamin B6 action in vivo may be used, and include, for example, pyridoxine, pyridoxamine, pyridoxal phosphate, and various physiologically acceptable esters and salts thereof. Examples of vitamin C include L-
Mention may be made of various physiologically acceptable salts such as the sodium salt of ascorbic acid or L-ascorbic acid and the calcium salt of L-ascorbic acid. As cysteines, it is possible to use, for example, physiologically acceptable salts such as L-cysteine or L-cysteine hydrochloride and L-cysteine sodium salt, and it is also possible to use glutathione. . Vitamin B1 may be any substance that exhibits the action of vitamin B1 in vivo, such as thiamine, thiamine hydrochloride, and disulfide thiamine, as well as various physiologically acceptable esters and salts thereof. can be mentioned. In the above-mentioned composition of the present invention, various vitamins such as vitamin E, pantothenic acid or its salts, pantethine, nicotinic acid amide, vitamin B12, etc.; choleretic agents; sugars; and Japanese and Chinese herbal medicines may be appropriately blended. be able to. [0006] The composition of the present invention can be provided in the form of a pharmaceutical or food product, and can be administered both orally and parenterally. Forms in which the composition of the present invention can be provided include commonly known dosage forms, for example, for oral administration,
Tablets, powders, granules, dragees, capsules and liquids, etc.
Parenteral administration includes suspensions, solutions, emulsions, ampoules and injections, and combinations of these can also be provided. At the time of formulation, additives commonly known in the field of formulations can be used as appropriate. [0007] Furthermore, the administration method, dosage and frequency of administration of the composition of the present invention are appropriately selected depending on the symptoms of the patient, and the dosage of each component can generally be selected within the following ranges. o Vitamin B2 types: approx. 5 mg to 100 mg/day o Vitamin B6 types: approx. 10 mg to 300 mg/day o Cysteine types: approx. 50 mg to 500 mg/day o Vitamin C types: approx. 200 mg to 5000 mg/day o Vitamin B1 types: approx. 5 mg to 200 mg/day Take the daily dose of 1 dose before drinking alcohol, after drinking alcohol, or before and after drinking alcohol.
-Administration may be divided into several doses. Next, the effects of the composition of the present invention will be explained by the expression of pharmacological effects upon administration of ethanol or acetaldehyde. The test was conducted using Test Methods 1 and 2. (1) It is a well-known phenomenon that alcohol causes paralysis of the limbs and a staggered gait. Even in animals, when a certain amount of ethanol or aldehyde is administered, the limbs become paralyzed and the gait becomes abnormal, which is not normal. You will not be able to hold on to metal rods that you can hold on to. Promoting ethanol metabolism and acetaldehyde metabolism and shortening the time of limb paralysis shows an effect of promoting sobriety during drinking, and is also important for the prevention and treatment of hangovers and bad intoxication. Ethanol metabolism and acetaldehyde metabolism promoting effects were investigated by the following test method 1. (2) Generally, one of the symptoms of a hangover caused by drinking alcohol is said to be abnormalities in gastrointestinal function such as gastrointestinal discomfort and loss of appetite. One of the common methods to measure gastrointestinal function in animals is to measure the intestinal charcoal transport ability, and since ethanol impairs and reduces the intestinal charcoal transport ability in mice, the effect of drugs on this is important. was investigated in Test Method 2. Below, those test methods are specifically described. Note that the dosage of each component used in the test is as shown in Table 1. In the case of doses other than these, the doses are written in parentheses (Table 7, Table 8). In addition, the ingredients of the formulations in Tables 2 to 9 are indicated by the abbreviations shown in Table 1. [Table 1] Each component used and its dosage ────────────────
──────────────────────
Ingredients
Abbreviation
Dose
(mg/kg)
────────────────────────
────────────── Riboflavin
VB2
100 Riboflavin butyrate
VB2but 1
00 Pyridoxine/HCl
VB6
200 L-ascorbic acid
VC
500 L-cysteine・HCl・
H2O Cys
300 Thiamine hydrochloride
VB1
200───────
──────────────────────────
──── (1) Test method 1 (ethanol metabolism and acetaldehyde metabolism promoting effect) DDY male mice (approximately 5 to 6 weeks old) are fasted for approximately 18 to 20 hours, and the test drug is orally administered. . Test drug administration 90
Minutes later, 3.1 ml/kg of ethanol or 200 mg/kg of acetaldehyde is administered intraperitoneally. When mice are administered ethanol or acetaldehyde, their limbs become paralyzed and they are unable to grasp a metal rod with a diameter of 1.5 mm, but they recover over time and are able to grasp. The paralysis time was measured as the time until the animal was able to grasp with three or more paws, including the two front paws. Note that ethanol and acetaldehyde were mixed with an appropriate amount of saline solution and administered. In addition, to the control group, only saline solution was administered at 0.1 ml per 10 g of mouse body weight. The results are shown in Tables 2 to 8. [Table 2] [Table 3] Effect of drug administration on the quadriplegic effect of acetaldehyde in mice ──────────
──────────────────────────
─ Prescription
Number of mice used Average paralysis time (seconds)────────────────────
──────────────── Control group
16 372±15.6
VB2but+VB6
15
284±18.5**────────────────
──────────────────────
t-te
st **P<0
.. [Table 4] [Table 5] [Table 6] Effect of drug administration on the quadriplegic effect of acetaldehyde in mice ──────────
──────────────────────────
Prescription
Number of mice used Average paralysis time (seconds) ──────────────────────
──────────────── Control group
12 434±37
Cys+VC+VB1
12
371±24 Cys+V
C+VB1+VB2but+VB6 12
313±12**
────────────────────────
────────────
t-test
**P<0.01 [0016] [Table 7] Effect of drug administration on the quadriplegic effect of ethanol in mice ────────────
────────────────────────
Prescription (dosage)
Number of mice used Average paralysis time (minutes)
(mg/kg)
──────
──────────────────────────
────── Control group
12
141±6.3C
ys+VC+VB1
12 126±8.
7 Cys+VC+VB1+VB2
but+VB6 12
96±11.3** Cys+VC
+VB1+VB2but+VB6 12
94± 9.9**
(160) (25) (20)
(100)
───
──────────────────────────
────────
t-test **P<
0.01 [Table 8] (2) Test method 2 After fasting male ddy mice (approximately 5 to 6 weeks old) for approximately 16 to 18 hours, the drug was orally administered, and the drug was administered for 1 hour. Afterwards, 4 ml/kg of ethanol is intraperitoneally administered. Ethanol administration 1.
After 5 hours, charcoal powder suspended in 0.25 ml of gum arabic liquid is orally administered. 40 minutes after administration of charcoal powder, the intestine of the mouse was removed and the length from the pylorus of the stomach to the tip of the charcoal powder (A),
and measure the length (B) from the pylorus of the stomach to the cecum,
Calculate the intestinal charcoal transport rate according to the following formula. The charcoal powder transport rate shows an average value of about 50 to 60% when ethanol is not administered (normal case), and decreases to a value of about 20 to 30% when 4 ml/kg of ethanol is intraperitoneally administered. Table 9 shows the results when the drug was administered at this time. [0019] [Table 9] [0020] Judging from the above results comprehensively, it was found that the present invention exerts an effect of promoting alcohol metabolism and acetaldehyde metabolism by using vitamin B2 and vitamin B6 in combination, Furthermore, a formulation containing vitamin C and cysteine in addition to vitamin B2 and vitamin B6, or a formulation containing vitamin C, cysteine and vitamin B1 in addition to vitamin B2 and vitamin B6. It can be seen that by doing so, a further enhanced effect is exhibited. Furthermore, the formulation containing vitamin B2 and vitamin B6 shows excellent effects and is also useful for preventing and treating gastrointestinal symptoms caused by hangovers caused by drinking alcohol. [Example] Next, formulations will be shown as examples, but the formulations are not limited to these. Example 1 Capsules having the following composition per capsule can be manufactured by known means. Example 2 Fine granules having the following composition per package can be produced by known means. Example 3 Fine granules having the following composition per package can be produced by known means. [0024] Effect of the invention: Vitamin B2 and vitamin B6 of the present invention
A combination of these drugs can promote alcohol metabolism and acetaldehyde metabolism, but in addition,
The formulation contains vitamin B2 and vitamin B6 as well as vitamin C and cysteine, or
Vitamin B2 and B6 as well as vitamin C,
By using a formulation containing cysteine and vitamin B1, a further enhanced effect is exhibited. Therefore, the present invention is useful for the prevention and treatment of hangovers and hangovers.
Claims (3)
6類を有効成分として含有することを特徴とするアルコ
ール代謝およびアセトアルデヒド代謝促進剤。[Claim 1] Vitamin B2 and vitamin B
An alcohol metabolism and acetaldehyde metabolism promoter characterized by containing Group 6 as an active ingredient.
6類に、更にビタミンC類およびシステイン類を含有し
てなる請求項1に記載のアルコール代謝およびアセトア
ルデヒド代謝促進剤。[Claim 2] Vitamin B2 and vitamin B
The alcohol metabolism and acetaldehyde metabolism promoter according to claim 1, which further contains vitamin C and cysteine in the 6th class.
6類に、更にビタミンC類、システイン類およびビタミ
ンB1類を含有してなる請求項1に記載のアルコール代
謝およびアセトアルデヒド代謝促進剤。[Claim 3] Vitamin B2 and vitamin B
The alcohol metabolism and acetaldehyde metabolism promoter according to claim 1, which further contains vitamin C, cysteine, and vitamin B1 in category 6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14124691A JPH04342528A (en) | 1991-05-17 | 1991-05-17 | Agent for promotion of alcohol metabolism and acetaldehyde metabolism |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14124691A JPH04342528A (en) | 1991-05-17 | 1991-05-17 | Agent for promotion of alcohol metabolism and acetaldehyde metabolism |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04342528A true JPH04342528A (en) | 1992-11-30 |
Family
ID=15287484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14124691A Pending JPH04342528A (en) | 1991-05-17 | 1991-05-17 | Agent for promotion of alcohol metabolism and acetaldehyde metabolism |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04342528A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006075059A (en) * | 2004-09-08 | 2006-03-23 | Asahi Breweries Ltd | Alcoholic beverage |
JP2007522254A (en) * | 2004-02-17 | 2007-08-09 | マルクス グラフ ヴィ. マツーシュカ−グライフェンクラウ | Alcohol metabolism regulating composition |
JP2009516639A (en) * | 2005-07-29 | 2009-04-23 | ティーマ ファウンデーション | Composition for reducing alcohol metabolism and reducing the risk of alcohol-induced diseases |
JP2010043085A (en) * | 2001-01-12 | 2010-02-25 | Innovation Ventures Llc | Activated charcoal-based composition and method for reducing hangover symptom associated with consumption of alcohol-containing beverages |
JP6009050B1 (en) * | 2015-08-21 | 2016-10-19 | 国立大学法人東北大学 | Reducing or preventing sickness or hangover caused by drinking |
WO2017161402A1 (en) * | 2016-03-24 | 2017-09-28 | Phoenix Pharmaceuticalsaustralia Pty Ltd | Formulation and method for the prevention and/or treatment of hangover symptoms |
-
1991
- 1991-05-17 JP JP14124691A patent/JPH04342528A/en active Pending
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010043085A (en) * | 2001-01-12 | 2010-02-25 | Innovation Ventures Llc | Activated charcoal-based composition and method for reducing hangover symptom associated with consumption of alcohol-containing beverages |
JP2013135686A (en) * | 2004-02-17 | 2013-07-11 | Markus Graf V Matuschka-Greiffenclau | Alcohol metabolism adjusting composition |
JP2007522254A (en) * | 2004-02-17 | 2007-08-09 | マルクス グラフ ヴィ. マツーシュカ−グライフェンクラウ | Alcohol metabolism regulating composition |
US20070218106A1 (en) * | 2004-02-17 | 2007-09-20 | Matuschka-Greiffenclau Markus | Alcohol Metabolism Moderating Composition |
JP2012092120A (en) * | 2004-02-17 | 2012-05-17 | Markus Graf V Matuschka-Greiffenclau | Alcohol metabolism modulating composition |
JP2006075059A (en) * | 2004-09-08 | 2006-03-23 | Asahi Breweries Ltd | Alcoholic beverage |
JP2009516639A (en) * | 2005-07-29 | 2009-04-23 | ティーマ ファウンデーション | Composition for reducing alcohol metabolism and reducing the risk of alcohol-induced diseases |
JP2013189437A (en) * | 2005-07-29 | 2013-09-26 | Tima Foundation | Composition for moderating alcohol metabolism and for reducing risk of alcohol induced disease |
US8580750B2 (en) | 2005-07-29 | 2013-11-12 | Tima Foundation | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
US9402849B2 (en) | 2005-07-29 | 2016-08-02 | Tima Foundation | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
JP6009050B1 (en) * | 2015-08-21 | 2016-10-19 | 国立大学法人東北大学 | Reducing or preventing sickness or hangover caused by drinking |
WO2017161402A1 (en) * | 2016-03-24 | 2017-09-28 | Phoenix Pharmaceuticalsaustralia Pty Ltd | Formulation and method for the prevention and/or treatment of hangover symptoms |
US20190105293A1 (en) * | 2016-03-24 | 2019-04-11 | Phoenix Pharmaceuticals Australia Pty Ltd | Formulation and method for the prevention and/or treatment of hangover symptoms |
US20210220313A1 (en) * | 2016-03-24 | 2021-07-22 | Phoenix Pharmaceuticals Australia Pty Ltd | Formulation and method for the prevention and/or treatment of hangover symptoms |
US11957650B2 (en) | 2016-03-24 | 2024-04-16 | Phoenix Pharmaceuticals Australia Pty Ltd | Formulation and method for the prevention and/or treatment of hangover symptoms |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090149518A1 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
US20050147665A1 (en) | Pharmaceutical and nutritional compositions | |
US6498247B2 (en) | Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions | |
KR20010013887A (en) | Composition for controlling mood disorders in healthy individuals | |
JP2016138142A (en) | Methods of providing weight loss therapy in patients with major depression | |
US20220378731A1 (en) | Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column | |
AU741511B2 (en) | Pharmaceutical composition comprising at least tyrosine and an iron compound fortreating parkinson's disease or depression | |
GB2368012A (en) | Preparation for the relief of inflammatory disease | |
JP3942207B2 (en) | Depressive symptom improving agent | |
US6017946A (en) | Serotonin containing formulation for oral administration and method of use | |
JP4786127B2 (en) | Antipigmentation treatment | |
US20140105878A1 (en) | Compositions and methods for prevention and treatment of migraines | |
JPH04342528A (en) | Agent for promotion of alcohol metabolism and acetaldehyde metabolism | |
JPH0699310B2 (en) | Acetaldehyde antidote | |
JP2002145779A (en) | Composition for treatment or prophylaxis of arthralgia | |
US20070292529A1 (en) | Strontium compositions and methods of treating osteoporotic conditions | |
WO2013016332A2 (en) | Composition and method for treating migraines | |
RU2404976C1 (en) | Agent to reduce alcohol addiction, pharmaceutical composition, method for making thereof, medicinal agent and method of treating | |
JP2004026846A (en) | Therapeutic or prophylactic composition for arthralgia | |
Sugar et al. | Clotiapine Toxicosis in a Puppy | |
CN105853473A (en) | Oxiracetam pharmaceutical composition and preparation method thereof | |
US9877951B2 (en) | Method for treating dementia | |
KR20210126644A (en) | Compositions and methods for the treatment of constipation and other diseases of the gastrointestinal system | |
DE102009040870B4 (en) | Modified colloidal precious metal for the treatment and prophylaxis of diseases | |
EP1518554A1 (en) | Pharmaceutical composition for the treatment of hyperhomocysteinemia |